A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer. - Wikidata - wikimedia - TriplyDB

A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer.

A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer.

http://www.wikidata.org/entity/Q34330748

about

Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives The treatment landscape in thyroid cancer: a focus on cabozantinib Ockham's razor for the MET-driven invasive growth linking idiopathic pulmonary fibrosis and cancer Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients.Treatment compliance and severe adverse events limit the use of tyrosine kinase inhibitors in refractory thyroid cancer.Treatment of distant metastases from follicular cell-derived thyroid cancer Selective use of vandetanib in the treatment of thyroid cancer.Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer.The Treatment of Advanced Thyroid Cancer in the Age of Novel Targeted Therapies.MET: roles in epithelial-mesenchymal transition and cancer stemness.Radioactive iodine-refractory differentiated thyroid cancer: an uncommon but challenging situation.Advances in small molecule therapy for treating metastatic thyroid cancer.Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK.Clinical guidance for radioiodine refractory differentiated thyroid cancer.Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial.Follicular cell-derived thyroid cancer.Application of genomics to identify therapeutic targets in recurrent pediatric papillary thyroid carcinoma.Navigating Systemic Therapy in Advanced Thyroid Carcinoma: From Standard of Care to Personalized Therapy and Beyond

P2860

Q26751274-59C40D83-631A-4126-846D-848F4744B0E8 Q26796404-DB681835-2EDC-408C-A8E0-36035025C207 Q28067777-658B0125-2443-4135-AEB6-1A704430E48B Q28072655-AAAE7ACE-9870-4FBD-9C02-145A3D743DD5 Q35057314-C9EF6326-D432-4449-8900-38E1EF6AD8FC Q36037051-E6BF4121-A75A-4F8A-A6AE-497CFF12F813 Q38370352-3498ECBE-0844-4216-BDD5-C0777C3CD4C0 Q38546474-366EAFA2-A049-4501-A564-DD52AAC70508 Q38823954-F9635411-FF6C-45AF-AEB8-FACD7F63C785 Q38865611-AFD4B08F-B896-43F5-B24A-51435A966C25 Q39121333-24574268-9049-48BB-B30B-5627468486B3 Q39146689-894F0902-F5C9-48C4-BF90-632030760FF2 Q39364787-5F386B15-3E3F-4501-BD68-0273DEFD49AF Q41099660-3B67C2F0-62C6-4EB2-AD1A-283981C12150 Q47863818-5D2A6407-B2F7-4CEA-BFCF-C10675C1EC34 Q47940756-09BD4062-68D6-4226-93C0-49A9DD14C4B4 Q48651339-FBCCF954-A29C-4E68-88F7-3165C69B79D1 Q55362706-D431194E-3D29-41BA-8151-3DF3837B7F01 Q58784257-9F631F66-4340-4009-9381-43B725B2B541

P2860

A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer.

http://www.wikidata.org/entity/Q34330748

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer.

@ast

A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer.

@en

A phase I study of cabozantinib

@nl

type

label

A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer.

@ast

A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer.

@en

A phase I study of cabozantinib

@nl

prefLabel

A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer.

@ast

A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer.

@en

A phase I study of cabozantinib

@nl

P1433

Q34330748-9D3E1BB9-EE82-4785-A6AE-1B77D46EFBD5

P1476

Q34330748-3DA3A81F-69C7-4F3C-9BB9-418D7D235882

P2093

Q34330748-071A195C-7B2D-4E29-BFD2-B513B19BDD31

Q34330748-160E0BBE-CDF3-4EAD-ABB8-DC23B20155E9

Q34330748-187A2DC1-856C-4A19-BE2F-0D2675670AE5

Q34330748-BACAFAB3-39FD-4F55-B918-7376F4CE1A2E

P2860

Q34330748-1CE3E621-4C0B-4719-A2C4-D3F633A615CD

Q34330748-1F727B9B-D1DC-4219-9211-3A0EE7EC5AE6

Q34330748-2661D467-1338-4D35-BE5E-F2F167C135C5

Q34330748-28476E96-A38E-4AFF-AC6E-E4B30D039419

Q34330748-2B8DC6F6-34DE-48A8-9D30-9BBAD59CDAC5

Q34330748-46247510-8479-447E-9D14-7111A23157CF

Q34330748-49CD5AF1-7106-42CB-884A-668EB70F3478

Q34330748-52EBA177-9F4C-479C-AB63-E590338F4AB8

Q34330748-5C93D21D-D677-46AF-AEB8-F36218DF5511

Q34330748-5CC1485C-596B-4DE6-8D4E-D63CCA16D33D

P304

Q34330748-12C24812-FDBB-4113-92C7-FF56D90E92D9

P31

Q34330748-BCF3C2A4-AC83-4FDC-888C-5B199D47AA81

P356

Q34330748-B2B1767B-4C9D-4FA8-844C-66D30E202DE1

P433

Q34330748-757003BE-CD04-44E1-B858-D4CED307CD17

P478

Q34330748-9432661C-CDC5-45E0-9607-6C244050E18E

P50

Q34330748-D14C4662-84D8-4CB6-8F79-199DE46FD5FD

P577

Q34330748-5A4E4C4E-6BD9-4173-9395-C28FA630DD44

P698

Q34330748-F6B50C4A-886C-4903-A88B-BF2442661660

P932

Q34330748-D7664B3A-23BE-4CB9-B626-D2B993091F5D

P356

P1433

P1476

A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer.

@en

P2093

Jaymes Holland

http://www.w3.org/2001/XMLSchema#string

Kimberly C Ferguson

http://www.w3.org/2001/XMLSchema#string

Marcia S Brose

http://www.w3.org/2001/XMLSchema#string

Maria E Cabanillas

http://www.w3.org/2001/XMLSchema#string

P2860

Sorafenib in metastatic thyroid cancer: a systematic review

Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directions

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer

Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib.

Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.

Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.

Cabozantinib in progressive medullary thyroid cancer.

Clinical features of metastatic bone disease and risk of skeletal morbidity.

Motesanib diphosphate in progressive differentiated thyroid cancer.

P304

1508-1514

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1089/THY.2014.0125

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

Steven I. Sherman

P577

2014-08-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25102375

http://www.w3.org/2001/XMLSchema#string

P932

4195402

http://www.w3.org/2001/XMLSchema#string